Interpretation and Management of Deranged INR in Non‑Warfarin Acutely Ill Patients

Validity of INR in Non‑Warfarin Settings

• Deranged INR in acutely ill patients not receiving warfarin most commonly reflects vitamin K deficiency, liver disease, or disseminated intravascular coagulation (DIC); it should not be interpreted as a predictor of bleeding risk nor as a trigger for plasma transfusion. 1
• The INR was specifically designed and validated only for monitoring vitamin K antagonist (warfarin) therapy and is therefore not a reliable general screen for coagulopathy. 1
• No high‑quality evidence supports the use of INR to predict bleeding risk or to guide plasma transfusion in patients who are not on warfarin. 1

Risks of Plasma Transfusion for Mild INR Elevations

• Transfusing plasma to “correct” a mildly elevated INR (< 2.0) in non‑bleeding, non‑warfarin patients lacks biological plausibility, does not reduce bleeding, and adds unnecessary transfusion‑related risks. 1
• Using INR as a general bleeding predictor in non‑warfarin patients has poor sensitivity and can provide false reassurance. 1

Disseminated Intravascular Coagulation (DIC) in COVID‑19

• Among COVID‑19 non‑survivors, 71.4 % develop DIC by day 4 of illness; this is accompanied by thrombocytopenia, markedly elevated D‑dimer, and a declining fibrinogen level. 2
• Evaluation for DIC in acutely ill patients should include platelet count, fibrinogen level, and D‑dimer measurement. 2

PT versus INR in Sepsis and Critical Illness

• Critically ill COVID‑19 patients who die exhibit modest PT prolongation (≈ 15.5 s) compared with survivors (≈ 13.6 s); reporting PT as INR can mask these clinically relevant differences. [3][4]
• In septic patients, elevated D‑dimer concentrations are more predictive of mortality than INR values. [3][4]

Elevated Coagulation Parameters Without Anticoagulant Use

Diagnostic Considerations

• The American College of Cardiology emphasizes that INR is a poor predictor of bleeding risk in liver disease patients, despite its use in MELD scoring, particularly in patients with known cirrhosis, hepatitis, elevated transaminases, or low albumin 5
• Early disseminated intravascular coagulation (DIC) can present with consumption of coagulation factors causing PT and APTT prolongation, often accompanied by thrombocytopenia and elevated D-dimer, especially in patients with sepsis, malignancy, trauma, or obstetric complications 6
• The American College of Cardiology and American Heart Association emphasize that INR was specifically designed and validated only for monitoring vitamin K antagonist therapy, not as a general bleeding predictor, with INR 1.4 being only mildly elevated and having poor sensitivity for predicting bleeding risk in patients not on warfarin 5
• The American Society of Hematology states that plasma transfusion to correct mildly elevated INR values lacks biological plausibility and exposes patients to unnecessary risk, as randomized trials found no reduction in bleeding when prophylactic plasma was given to correct INR values 5
• The American College of Surgeons recommends viscoelastic testing, such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM), when available for optimizing coagulation function assessment, particularly in liver disease where PT/INR is unreliable 5
• Direct oral anticoagulant use can prolong both PT and APTT, and it is essential to confirm no recent use, according to the Journal of the American College of Cardiology 7